Oncolytic virotherapy of breast cancer

Gynecologic Oncology

Volumn 123, Issue 1, 2011, Pages 164-171

  Hartkopf, Andreas D ^a   Fehm, Tanja ^a   Wallwiener, Diethelm ^a   Lauer, Ulrich M ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer; Oncolytic virus; Virotherapy

Indexed keywords

DL 922947; MEASLES VACCINE VIRUS CARCINOEMBRYONIC ANTIGEN; ONCOLYTIC VIRUS; ONYX 015; REOLYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CLINICAL TRIAL (TOPIC); GENE THERAPY; HUMAN; MEASLES VACCINE VIRUS; MEASLES VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARVOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; REOVIRUS; REVIEW; TRANSGENE; VACCINIA VIRUS; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 80052579640     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.06.021     Document Type: Review

References (116)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. V. Guarneri, and P.F. Conte The curability of breast cancer and the treatment of advanced disease Eur J Nucl Med Mol Imaging 31 Suppl. 1 2004 S149 S161
3. D. Kirn, R.L. Martuza, and J. Zwiebel Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 7 2001 781 787 (Pubitemid 32691631)
4. R. Strauss, and A. Lieber Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo Mol Ther 11 2009 513 522
5. M. Bitzer, and U.M. Lauer Oncolytic viruses for genetic therapy of gastrointestinal tumors Z Gastroenterol 41 2003 667 674 (Pubitemid 36916972)
6. T. Ichikawa, and E.A. Chiocca Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector Cancer Res 61 2001 5336 5339 (Pubitemid 32694905)
7. G. Muharram, E. Le Rhun, I. Loison, P. Wizla, A. Richard, and N. Martin Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures Breast Cancer Res Treat 121 2010 23 33
8. J. Rommelaere, K. Geletneky, A.L. Angelova, L. Daeffler, C. Dinsart, and I. Kiprianova Oncolytic parvoviruses as cancer therapeutics Cytokine Growth Factor Rev 21 2010 185 195
9. T. Dupressoir, J.M. Vanacker, J.J. Cornelis, N. Duponchel, and J. Rommelaere Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells Cancer Res 49 1989 3203 3208 (Pubitemid 19162125)
10. K. Geletneky, A.D. Hartkopf, R. Krempien, J. Rommelaere, and J.R. Schlehofer Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection J Biomed Biotechnol 2010 2010 350748
11. K. Geletneky, A.D. Hartkopf, R. Krempien, J. Rommelaere, and J.R. Schlehofer Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic Parvovirus H-1 infection in high-grade glioma cells Bioengineered Bugs 1 2010 1 5
12. Messer HGP, Xiang Y, Agbandje-McKenna M, K. KA, Aken W-V. Retargeting Parvovirus B19 to HER2/neu-Positive Cells for Breast Cancer Treatment. Mol Ther 2011;19:S1.
13. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
14. A. Moliterni, S. Menard, P. Valagussa, E. Biganzoli, P. Boracchi, and A. Balsari HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer J Clin Oncol 21 2003 458 462 (Pubitemid 46606475)
15. A.Z. Bluming, and J.L. Ziegler Regression of Burkitt's lymphoma in association with measles infection Lancet 2 1971 105 106
16. S. Gross Measles and leukaemia Lancet 1 1971 397 398
17. H.C. Mota Infantile Hodgkin's disease: remission after measles Br Med J 2 1973 421
18. G. Pasquinucci Possible effect of measles on leukaemia Lancet 1 1971 136
19. Z. Zygiert Hodgkin's disease: remissions after measles Lancet 1 1971 593
20. R.E. Dorig, A. Marcil, A. Chopra, and C.D. Richardson The human CD46 molecule is a receptor for measles virus (Edmonston strain) Cell 75 1993 295 305 (Pubitemid 23320293)
21. L. Bjorge, J. Hakulinen, T. Wahlstrom, R. Matre, and S. Meri Complement-regulatory proteins in ovarian malignancies Int J Cancer 70 1997 14 25 (Pubitemid 27059700)
22. B.D. Anderson, T. Nakamura, S.J. Russell, and K.W. Peng High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus Cancer Res 64 2004 4919 4926 (Pubitemid 38924538)
23. C.J. McDonald, C. Erlichman, J.N. Ingle, G.A. Rosales, C. Allen, and S.M. Greiner A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer Breast Cancer Res Treat 99 2006 177 184 (Pubitemid 44268265)
24. K.W. Peng, S. Facteau, T. Wegman, D. O'Kane, and S.J. Russell Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides Nat Med 8 2002 527 531 (Pubitemid 34546758)
25. I.D. Iankov, P. Msaouel, C. Allen, M.J. Federspiel, P.A. Bulur, and A.B. Dietz Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model Breast Cancer Res Treat 122 2009 745 754
26. E. Galanis, L.C. Hartmann, W.A. Cliby, H.J. Long, P.P. Peethambaram, and B.A. Barrette Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Cancer Res 70 2010 875 882
27. J.E. Strong, M.C. Coffey, D. Tang, P. Sabinin, and P.W. Lee The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus EMBO J 17 1998 3351 3362 (Pubitemid 28279509)
28. M.C. Coffey, J.E. Strong, P.A. Forsyth, and P.W. Lee Reovirus therapy of tumors with activated Ras pathway Science 282 1998 1332 1334 (Pubitemid 28524498)
29. J. Zhang, X. Liu, A. Datta, K. Govindarajan, W.L. Tam, and J. Han RCP is a human breast cancer-promoting gene with Ras-activating function J Clin Invest 119 2009 2171 2183
30. K.L. Norman, M.C. Coffey, K. Hirasawa, D.J. Demetrick, S.G. Nishikawa, and L.M. DiFrancesco Reovirus oncolysis of human breast cancer Hum Gene Ther 13 2002 641 652 (Pubitemid 34264314)
31. W.Q. Yang, D.L. Senger, X.Q. Lun, H. Muzik, Z.Q. Shi, and R.H. Dyck Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer Gene Ther 11 2004 1579 1589 (Pubitemid 39433478)
32. R. Lal, D. Harris, S. Postel-Vinay, and J. de Bono Reovirus: rationale and clinical trial update Curr Opin Mol Ther 11 2009 532 539
33. R. Gollamudi, M.H. Ghalib, K.K. Desai, I. Chaudhary, B. Wong, and M. Einstein Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors Invest New Drugs 28 2010 641 649
34. C.M. Vollmer, A. Ribas, L.H. Butterfield, V.B. Dissette, K.J. Andrews, and F.C. Eilber p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma Cancer Res 59 1999 4369 4374 (Pubitemid 29418756)
35. C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, and A. Williams An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 6 2000 1134 1139
36. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
37. E.A. McKie, A.R. MacLean, A.D. Lewis, G. Cruickshank, R. Rampling, and S.C. Barnett Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy Br J Cancer 74 1996 745 752 (Pubitemid 26300766)
38. J.C. Kucharczuk, B. Randazzo, M.Y. Chang, K.M. Amin, A.A. Elshami, and D.H. Sterman Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma Cancer Res 57 1997 466 471 (Pubitemid 27081665)
39. B.P. Randazzo, M.G. Bhat, S. Kesari, N.W. Fraser, and S.M. Brown Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant J Invest Dermatol 108 1997 933 937 (Pubitemid 27272413)
40. J.M. Markert, P.G. Liechty, W. Wang, S. Gaston, E. Braz, and M. Karrasch Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM Mol Ther 17 2009 199 207
41. J.M. Markert, M.D. Medlock, S.D. Rabkin, G.Y. Gillespie, T. Todo, and W.D. Hunter Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 7 2000 867 874 (Pubitemid 30303584)
42. M. Toda, S.D. Rabkin, and R.L. Martuza Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1 Hum Gene Ther 9 1998 2177 2185 (Pubitemid 28498004)
43. R. Liu, R.L. Martuza, and S.D. Rabkin Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain Gene Ther 12 2005 647 654 (Pubitemid 40561503)
44. T. Todo, R.L. Martuza, S.D. Rabkin, and P.A. Johnson Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing Proc Natl Acad Sci U S A 98 2001 6396 6401 (Pubitemid 32488248)
45. R. Liu, S. Varghese, and S.D. Rabkin Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice Cancer Res 65 2005 1532 1540 (Pubitemid 40270182)
46. K.L. Mossman, H.A. Saffran, and J.R. Smiley Herpes simplex virus ICP0 mutants are hypersensitive to interferon J Virol 74 2000 2052 2056 (Pubitemid 30434066)
47. F. Yao, and P.A. Schaffer An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1 J Virol 69 1995 6249 6258
48. J.L. Hummel, E. Safroneeva, and K.L. Mossman The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma Mol Ther 12 2005 1101 1110 (Pubitemid 41723044)
49. H. Kimata, T. Imai, T. Kikumori, O. Teshigahara, T. Nagasaka, and F. Goshima Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer Ann Surg Oncol 13 2006 1078 1084 (Pubitemid 44337967)
50. G.W. Milton, and M.M. Brown The limited role of attenuated smallpox virus in the management of advanced malignant melanoma Aust N Z J Surg 35 1966 286 290
51. I. Hunter-Craig, K.A. Newton, G. Westbury, and B.W. Lacey Use of vaccinia virus in the treatment of metastatic malignant melanoma Br Med J 2 1970 512 515
52. S. Arakawa Jr., G. Hamami, K. Umezu, S. Kamidono, J. Ishigami, and S. Arakawa Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases J Cancer Res Clin Oncol 113 1987 95 98 (Pubitemid 17017575)
53. A. Kawa, and S. Arakawa The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report Jpn J Exp Med 57 1987 79 81 (Pubitemid 17067625)
54. N.G. Chen, and A.A. Szalay Oncolytic vaccinia virus: a theranostic agent for cancer Future Virol 5 2010 763 784
55. Q. Zhang, Y.A. Yu, E. Wang, N. Chen, R.L. Danner, and P.J. Munson Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus Cancer Res 67 2007 10038 10046 (Pubitemid 47621255)
56. K.J. Kelly, P. Brader, Y. Woo, S. Li, N. Chen, and Y.A. Yu Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model Int J Cancer 124 2009 911 918
57. H.J. Zeh, M. O'Malley, H. Jones, D.H. Kirn, M. Anne, and H.H. Tae Clinical trial results: intralesional injection of a tumor selective oncolytic vaccinia virus Mol Ther 19 2011 S229
58. D.F. Stojdl, B.D. Lichty, B.R. tenOever, J.M. Paterson, A.T. Power, and S. Knowles VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263 275 (Pubitemid 37329791)
59. O. Ebert, S. Harbaran, K. Shinozaki, and S.L. Woo Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice Cancer Gene Ther 12 2005 350 358 (Pubitemid 40411194)
60. M. Ahmed, S. Puckett, and D.S. Lyles Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus Cancer Gene Ther 17 2010 883 892
61. D.M. Shayakhmetov, Z.Y. Li, S. Ni, and A. Lieber Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases Cancer Res 62 2002 1063 1068 (Pubitemid 34160288)
62. T. Ranki, M. Sarkioja, T. Hakkarainen, K. von Smitten, A. Kanerva, and A. Hemminki Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer Int J Cancer 121 2007 165 174 (Pubitemid 46753865)
63. A. Hemminki, N. Belousova, K.R. Zinn, B. Liu, M. Wang, and T.R. Chaudhuri An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression Mol Ther 4 2001 223 231 (Pubitemid 32851286)
64. T. Ranki, A. Kanerva, A. Ristimaki, T. Hakkarainen, M. Sarkioja, and L. Kangasniemi A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer Gene Ther 14 2007 58 67 (Pubitemid 44942866)
65. D.T. Curiel, M. Preuss, M. Wang, K.J. Kimball, M.N. Barnes, and W. Wan A phase I study of the infectivity enhanced CRAd Ad5-delta24RGD for recurrent gynecologic cancer J Clin Oncol 28 2010 15s (abstr 5107)
66. I. Bergman, P. Whitaker-Dowling, Y. Gao, and J.A. Griffin Preferential targeting of vesicular stomatitis virus to breast cancer cells Virology 330 2004 24 33 (Pubitemid 39446564)
67. I. Bergman, J.A. Griffin, Y. Gao, and P. Whitaker-Dowling Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu Int J Cancer 121 2007 425 430 (Pubitemid 46917713)
68. L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, and C. De Giovanni Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells Proc Natl Acad Sci U S A 106 2009 9039 9044
69. Y. Jing, C. Tong, J. Zhang, T. Nakamura, I. Iankov, and S.J. Russell Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor Cancer Res 69 2009 1459 1468
70. J.H. de Witte, J.A. Foekens, N. Brunner, J.J. Heuvel, T. van Tienoven, and M.P. Look Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours Br J Cancer 85 2001 85 92 (Pubitemid 32695721)
71. R. Cattaneo, T. Miest, E.V. Shashkova, and M.A. Barry Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded Nat Rev Microbiol 6 2008 529 540 (Pubitemid 351850977)
72. B. Falgout, and G. Ketner Adenovirus early region 4 is required for efficient virus particle assembly J Virol 61 1987 3759 3768 (Pubitemid 18011473)
73. W.K. Cho, Y.R. Seong, Y.H. Lee, M.J. Kim, K.S. Hwang, and J. Yoo Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor Mol Ther 10 2004 938 949 (Pubitemid 39419919)
74. R. Hernandez-Alcoceba, M. Pihalja, D. Qian, and M.F. Clarke New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication Hum Gene Ther 13 2002 1737 1750 (Pubitemid 35191748)
75. R. Hernandez-Alcoceba, M. Pihalja, M.S. Wicha, and M.F. Clarke A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors Hum Gene Ther 11 2000 2009 2024
76. P.F. Searle, M.J. Chen, L. Hu, P.R. Race, A.L. Lovering, and J.I. Grove Nitroreductase: a prodrug-activating enzyme for cancer gene therapy Clin Exp Pharmacol Physiol 31 2004 811 816 (Pubitemid 39556859)
77. S. Lal, U.M. Lauer, D. Niethammer, J.F. Beck, and P.G. Schlegel Suicide genes: past, present and future perspectives Immunol Today 21 2000 48 54 (Pubitemid 30410699)
78. J.A. Bridgewater, C.J. Springer, R.J. Knox, N.P. Minton, N.P. Michael, and M.K. Collins Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 Eur J Cancer 31A 1995 2362 2370 (Pubitemid 26053242)
79. E. Garcia-Aragoncillo, and R. Hernandez-Alcoceba Design of virotherapy for effective tumor treatment Curr Opin Mol Ther 12 2010 403 411
80. J.F. Zhang, C. Hu, Y. Geng, J. Selm, S.B. Klein, and A. Orazi Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy Proc Natl Acad Sci U S A 93 1996 4513 4518 (Pubitemid 26144318)
81. J.C. Hu, R.S. Coffin, C.J. Davis, N.J. Graham, N. Groves, and P.J. Guest A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin Cancer Res 12 2006 6737 6747 (Pubitemid 44876843)
82. M. Toda, R.L. Martuza, and S.D. Rabkin Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor Mol Ther 2 2000 324 329
83. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 1997 730 737 (Pubitemid 27298715)
84. C.A. O'Brien, A. Pollett, S. Gallinger, and J.E. Dick A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Nature 445 2007 106 110 (Pubitemid 46067310)
85. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, and C. Peschle Identification and expansion of human colon-cancer-initiating cells Nature 445 2007 111 115 (Pubitemid 46067311)
86. M.E. Prince, R. Sivanandan, A. Kaczorowski, G.T. Wolf, M.J. Kaplan, and P. Dalerba Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proc Natl Acad Sci U S A 104 2007 973 978 (Pubitemid 46154721)
87. D. Dingli, and F. Michor Successful therapy must eradicate cancer stem cells Stem Cells 24 2006 2603 2610 (Pubitemid 46052998)
88. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 2005 275 284 (Pubitemid 40488633)
89. T.P. Cripe, P.Y. Wang, P. Marcato, Y.Y. Mahller, and P.W. Lee Targeting cancer-initiating cells with oncolytic viruses Mol Ther 17 2009 1677 1682
90. -/low cells Mol Ther 15 2007 2088 2093 (Pubitemid 350148923)
91. P. Marcato, C.A. Dean, C.A. Giacomantonio, and P.W. Lee Oncolytic reovirus effectively targets breast cancer stem cells Mol Ther 17 2009 972 979
92. S. Gholami, C.-H. Chen, J.S. Carson, D. Haddad, S. Taejin, and J. Au Oncolytic viruses: a novel therapy against triple-negative breast cancer Mol Ther 19 2011 S260
93. Y. Wang, S. Thorne, J. Hannock, J. Francis, T. Au, and T. Reid A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses Clin Cancer Res 11 2005 351 360 (Pubitemid 40075815)
94. M.G. Rots, M.G. Elferink, W.M. Gommans, D. Oosterhuis, J.A. Schalk, and D.T. Curiel An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents J Gene Med 8 2006 35 41 (Pubitemid 43169379)
95. M. Zimmermann, S. Armeanu, I. Smirnow, S. Kupka, S. Wagner, and M. Wehrmann Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses Int J Oncol 34 2009 1247 1256
96. H. Choi, C. Charnsangavej, S.C. Faria, H.A. Macapinlac, M.A. Burgess, and S.R. Patel Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759 (Pubitemid 46797957)
97. T.C. Liu, and D. Kirn Gene therapy progress and prospects cancer: oncolytic viruses Gene Ther 15 2008 877 884 (Pubitemid 351791475)
98. M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, J. Matera, and M.C. Miller Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 2004 781 791 (Pubitemid 39095313)
99. D.F. Hayes, M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, and M.C. Miller Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival Clin Cancer Res 12 2006 4218 4224
100. J.C. Hu, M.J. Booth, G. Tripuraneni, D. Davies, S.A. Zaidi, and M. Tamburo de Bella A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow Clin Cancer Res 12 2006 6853 6862 (Pubitemid 44876856)
101. C.M. Thirukkumaran, J.M. Luider, D.A. Stewart, T. Alain, J.A. Russell, and I.A. Auer Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts Bone Marrow Transplant 35 2005 1055 1064 (Pubitemid 40767193)
102. T. Kottke, G. Hall, J. Pulido, R.M. Diaz, J. Thompson, and H. Chong Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice J Clin Invest 120 2010 1551 1560
103. K.A. Skelding, R.D. Barry, and D.R. Shafren Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21 Breast Cancer Res Treat 113 2009 21 30
104. A. Phuangsab, R.M. Lorence, K.W. Reichard, M.E. Peeples, and R.J. Walter Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration Cancer Lett 172 2001 27 36 (Pubitemid 32823469)
105. O. Teshigahara, F. Goshima, K. Takao, S. Kohno, H. Kimata, and A. Nakao Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10 J Surg Oncol 85 2004 42 47 (Pubitemid 38036739)
106. H. Li, A. Dutuor, X. Fu, and X. Zhang Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model J Gene Med 9 2007 161 169 (Pubitemid 46523534)
107. Z.B. Zhu, S.K. Makhija, B. Lu, M. Wang, A.A. Rivera, and S. Kim-Park Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo Int J Oncol 27 2005 237 246
108. L. Zhang, H. Akbulut, Y. Tang, X. Peng, G. Pizzorno, and E. Sapi Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma Mol Ther 6 2002 386 393 (Pubitemid 36305341)
109. Z. Hu, J.S. Robbins, A. Pister, M.B. Zafar, Z.W. Zhang, and J. Gupta A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy Cancer Gene Ther 17 2009 235 243
110. Z. Hu, Z. Zhang, T. Guise, and P. Seth Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-beta receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model Hum Gene Ther 21 2010 1623 1629
111. Z. Hu, H. Gerseny, Z. Zhang, and S. Stock Oncolytic adenoviral-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer Mol Ther 19 2011 S258
112. E.M. Gomes, M.S. Rodrigues, A.P. Phadke, L.D. Butcher, C. Starling, and S. Chen Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells Clin Cancer Res 15 2009 1317 1325
113. J.Y. Yoo, J.H. Kim, J. Kim, J.H. Huang, S.N. Zhang, and Y.A. Kang Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition Gene Ther 15 2008 635 651 (Pubitemid 351524518)
114. D. Sarkar, Z.Z. Su, N. Vozhilla, E.S. Park, P. Gupta, and P.B. Fisher Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice Proc Natl Acad Sci U S A 102 2005 14034 14039 (Pubitemid 41377698)
115. M. Fernandez, M. Porosnicu, D. Markovic, and G.N. Barber Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease J Virol 76 2002 895 904 (Pubitemid 34033386)
116. C.M. Seubert, J. Stritzker, M. Hess, U. Donat, J.B. Sturm, and N. Chen Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-activatable prodrug seco-analog of duocarmycin SA Cancer Gene Ther 18 2010 42 52